I found an article this week that gives me a bit of hope. I would be surprised if a vaccine were released to the public this year. The effectiveness and efficacy of a vaccine are determined in clinical tests. The real effectiveness is not known until it has been released to the public.
Several companies around the world are working on COVID-19 vaccines. One vaccine, mRNA-1273, is showing promise and should be in Phase 3 clinical testing this month. A vaccine causes our bodies to produce antibodies to give us immunity to a disease.
Immunity, prevention, and correction are different when it comes to fighting COVID-19. Hydroxychloroquine has shown significant corrective properties and is undergoing additional testing. Remdesivir has gotten good publicity but is not effective against severe cases of COVID-19. What else is available?
The Science Translational Medicine journal (https://stm.sciencemag.org/content/12/555/eabc9396) reported findings recently on an enzyme that might prevent COVID-19. Coronaviruses have a protease that breaks down proteins and peptides. It is an enzyme called a 3C-like protease.
If there is a way to short-circuit or disrupt the 3C-like protease enzyme, then RNA viruses cannot replicate. An inhibiting compound called GC376 has success in laboratory animals. Survival rates for mice with MERS were improved. The SARS-CoV-2 virus responsible for COVID-19 was neutralized with GC376.
Additional testing with felines showed remarkable recovery in a coronavirus caused disease that was always 100% fatal. Two out of twenty-two compounds showed potency in combatting coronaviruses. 6e was the most potent compound in neutralizing the SARS-CoV-2 virus. 6J also inhibited the SARS-CoV-2 virus and extremely effective against the MERS-CoV virus.
Animal studies do not automatically prove efficacy in humans. However, the proof of concept to stop viral replication has been established. Studies are ongoing to evaluate treatment for both MERS and COVID-19 in humans.
Live Longer & Enjoy Life! – Red O’Laughlin – RedOLaughlin.com